Synopsys, Inc. (SNPS) Reports In-Line Q4 EPS; Guides Q1, FY12 EPS, Revs
Tweet
Share
E-mailGet Alerts SNPS Hot Sheet
Price: $527.52 --0%
EPS Growth %: +20.5%
Financial Fact:
Provision (benefit) for income taxes: 10.06M
Today's EPS Names:
UXIN, TOWN, NRIM, More
EPS Growth %: +20.5%
Financial Fact:
Provision (benefit) for income taxes: 10.06M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Join SI Premium – FREE
Synopsys, Inc. (NASDAQ: SNPS) reported Q4 EPS of $0.45, in-line with the analyst estimate of $0.45. Revenue for the quarter came in at $390.5 million versus the consensus estimate of $390.11 million.
Synopsys, Inc. sees Q1 2012 EPS of $0.51-$0.53, versus the consensus of $0.46. Synopsys, Inc. sees Q1 2012 revenue of $412-$420 million, versus the consensus of $389.0 million.
Synopsys, Inc. sees FY2012 EPS of $1.93-$1.99, versus the consensus of $1.96. Synopsys, Inc. sees FY2012 revenue of $1.64-$1.665 billion, versus the consensus of $1.65 billion.
Synopsys, Inc. sees Q1 2012 EPS of $0.51-$0.53, versus the consensus of $0.46. Synopsys, Inc. sees Q1 2012 revenue of $412-$420 million, versus the consensus of $389.0 million.
Synopsys, Inc. sees FY2012 EPS of $1.93-$1.99, versus the consensus of $1.96. Synopsys, Inc. sees FY2012 revenue of $1.64-$1.665 billion, versus the consensus of $1.65 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Sanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy
- AstraZeneca (AZN) Tops Q1 EPS by 110c; reaffirms guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
